Wednesday, April 24, 2024
HomeRecent ArticlesIsrael-based Vessi Medical Secures $16.5 Mn Series A Funding

Israel-based Vessi Medical Secures $16.5 Mn Series A Funding

Vessi Medical, an Israeli medical device startup has secured $16.5 Million in series A funding round. The investors in the funding round are included: ALIVE-Israel HealthTech Fund, Agriline, and the founding investor The Trendlines Group.

Read also – solutions by stc and Devoteam Global Group Join Forces Through Signing an MoU

Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets.

Read also – Param Labs and Animoca Brands Partner to Innovate and Advance Gaming Industry in MENA and beyond

Vessi Medical founder & CEO Eyal Kochavi said,, “The participation of a global strategic investor in this round is a huge show of confidence in Vessi’s achievements and potential. The financing led by ALIVE will support expanding Vessi’s R&D capabilities, clinical studies in Israel and the US, and regulatory clearance, enabling us to achieve our goal of bringing Vessi’s treatment for NMIBC to patients and physicians to reduce side effects, improve patient outcomes, and lower health care costs.”

Read also – UAE’s Technology Innovation Institute Launches ‘Falcon Foundation’ to Champion Open-Sourcing of Generative AI Models

Vincent Tchenguiz, owner of Consensus Business Group and Agriline discretionary beneficiary said, “Positioned at the vanguard of technological advancement, Vessi Medical’s cutting-edge cryotherapy for NMIBC heralds a transformative shift in both cancer care and health economics. Our investment is a testament to our confidence in Vessi’s revolutionary potential to not only enhance patient outcomes but also to redefine care standards, alleviate suffering, and spearhead the development of more compassionate and efficacious treatment modalities.”

Read also – Jordan-based Sowt Media Acquires Rising Giants Network

About Vessi Medical

Vessi’s minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company’s patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage.

Read also – EV logistics Platform Mober Secures US $2Mn Seed Funding

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular